Background. Lipoproteins may contribute to diabetic nephropathy. Nuclear magnetic resonance (NMR) can quantify subclasses and mean particle size of very low density lipoprotein (VLDL), low density lipoprotein (LDL), and high density lipoprotein (HDL), and LDL particle concentration. The relationship between detailed lipoprotein analyses and diabetic nephropathy is of interest.
are needed to determine if dyslipoproteinemia can predict patients at risk of nephropathy, or if lipoprotein-related interventions retard nephropathy.
Diabetes is the leading cause of end-stage renal disease in the United States [1] . In diabetes, microalbuminuria is predictive of future proteinuria, progressive decline in renal function, aggressive retinopathy, accelerated atherosclerosis, and premature mortality predominantly from coronary artery disease [1] [2] [3] [4] . Factors implicated in the development of nephropathy and other micro-and macrovascular complications include long duration of diabetes, poor glycemic control, smoking, and hypertension [2, 4] . Dyslipidemia has also been associated with the development and progression of nephropathy and other vascular complications [5] [6] [7] , and lipid lowering may retard renal damage [8] .
In type 1 diabetes with good to moderate glycemic control, total and low density lipoprotein (LDL) cholesterol and triglyceride levels are usually within the normal range. HDL cholesterol levels are also typically normal, or even elevated [9] . However, HDL can be subdivided into at least 2 major subclasses, which are thought to differ in ability to protect against atherosclerosis [10] . Apparently, favorable total HDL levels may be comprised of relatively high levels of non-cardioprotective, small HDL. Levels of IDL may be increased, particularly in the presence of proteinuria [6] , but are not readily measured. Each major lipoprotein class is heterogeneous in size and density [5, 6, [9] [10] [11] , and subtle changes in lipoproteins may be relevant to the cause and to the prevention of nephropathy and the associated accelerated atherosclerosis.
In this large cross-sectional study, we assessed the relationship between dyslipidemia and nephropathy in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort of subjects with type 1 diabetes [12] . Detailed lipoprotein analyses were performed, including a conventional lipid profile, a nuclear magnetic resonance (NMR) lipoprotein subclass profile (NMR-LSP), levels of apolipoprotein A1 and B (apoA1, apoB) and of lipoprotein(a) [Lp(a)], and susceptibility of isolated LDL to oxidation.
METHODS

Study subjects
The original DCCT cohort consisted of 1441 men and women aged 13 to 39 years with type 1 diabetes for 1 to 15 years at study entry between 1983 and 1989 [12, 13] . The study was designed to determine if intensive therapy with the aim of maintaining blood glucose as close to the normal range as possible would prevent or delay long-term complications, with retinopathy being the primary end point. There were primary and secondary prevention cohorts; the former consisted of 726 patients with diabetes of 1 to 5 years' duration who, at study entry, had no retinopathy and urinary albumin excretion rate (AER) Ͻ28 g/min (40 mg/24 hr). The secondary prevention cohort consisted of 715 patients who had had diabetes for 1 to 15 years and who had minimal-tomoderate nonproliferative retinopathy and urinary AER Ͻ139 g/min (Ͻ200 mg/24 hr). Subjects were randomly assigned to conventional (N ϭ 730) and intensive (N ϭ 711) diabetes treatment [12] . In 1993, after a mean follow-up time of 6.5 years, the DCCT was stopped because of major beneficial effect of intensive therapy on retinal, renal, and neurologic complications [12] . All DCCT subjects were then invited to join EDIC, an ongoing longitudinal epidemiologic investigation [14] . The primary goal of EDIC, an observational and not an interventional study, was to study macrovascular disease in type 1 diabetes, and an additional goal was to assess risk factors for nephropathy.
Each EDIC subject annually underwent a standardized history and physical examination, including a detailed evaluation of overall health, diabetes management, occurrence of diabetic complications, and medications used [14, 15] . Hemoglobin A1c (HbA 1c ) was determined annually by high performance liquid chromatography (HPLC) in the DCCT/EDIC central laboratory, as previously described [13] . Fasting lipid profiles were also determined in the DCCT/EDIC central laboratory in alternate years. AER and calculated creatinine clearance were determined in the DCCT/EDIC central laboratory using 4 hour urine collections performed the same day as the blood was drawn [14] . Retinopathy was assessed at the annual visit alternating from the one at which the fasting blood sample was obtained. Retinopathy was assessed by fundus photography, and all photographs were graded centrally according to the final Early Treatment Diabetic Retinopathy Study (ETDRS) grading scale [16] and DCCT methods as previously described [15] .
In 1996, a collaborative project between investigators at the Medical University of South Carolina (MUSC) and DCCT/EDIC was implemented. Its primary goal was to identify risk factors and mechanisms for vascular disease in type 1 diabetes using samples shipped directly from participating centers to MUSC. Twenty-five of the 28 DCCT/EDIC centers participated and between 1997 to 1999, fasting plasma and serum samples were sent to MUSC. The MUSC group used these samples to determine NMR-LSP, apoA1, apoB, and Lp(a). In addition, we isolated LDL and studied the susceptibility of its protein (N ϭ 729) and lipid (N ϭ 726) components to oxidative damage. Conventional lipid profiles were determined by the DCCT/EDIC central laboratory (as described below). The blood samples sent to MUSC were obtained from the same blood drawn as the samples for the DCCT/EDIC central laboratory.
The study was approved by the Institutional Review Boards of MUSC and participating DCCT/EDIC centers. Written informed consent was obtained from all participating subjects. The 968 subjects with type 1 diabetes in whom detailed lipoprotein analyses were performed represent 73% of the original DCCT/EDIC cohort, and their characteristics did not differ significantly from the entire cohort. Clinical data were obtained according to the EDIC protocol [14, 15] . We categorized subjects into 3 groups according to AER: normal (Ͻ40 mg/24 hr); microalbuminuria (40 to 299 mg/24 hr); and albuminuria (Ն300 mg/24 hr). Subjects were also categorized as having normal, elevated, or low creatinine clearance. Normal creatinine clearance was considered to be 97 to 137 mL/min for men and 88 to 128 mL/min for women [17] .
Sample collection
To obtain serum, blood was collected into a Falcon tube (Norcross, Fisher, GA, USA) containing polypropylene beads (Sarstedt, Newton, NC, USA) by venipuncture after an overnight fast and prior to insulin administration. To obtain plasma for LDL preparation, 55 mL of blood was drawn into Falcon tubes containing a lipoprotein preservative solution comprised of 2.8 mmol/L ethylenediaminetetraacetic acid (EDTA), 62 mol/L chloramphenicol, 50 g/mL gentamycin sulfate, and 10 mmol/L ε-aminocaproic-acid (final concentrations). Serum and plasma were prepared by centrifugation (3000 rpm, 20 min), and shipped overnight on wet ice to MUSC, where LDL was isolated from plasma (as described below) beginning on day of receipt, and serum [for analysis by NMR and for apolipoproteins and Lp(a) levels] was stored at Ϫ70ЊC for subsequent analyses. Plasma and serum collected on Fridays were stored at 4ЊC until shipment to MUSC the following Monday.
Blood samples taken at the same venipuncture were sent to the DCCT/EDIC Central Biochemistry Laboratory (CBL, Fairview University Medical Center, University of Minnesota) for determination of the conventional lipid profile, HbA 1c , and serum creatinine.
Conventional lipid profile
Total cholesterol was determined by a cholesterol oxidase method and total triglyceride by an enzymatic method utilizing an automated glycerol blank (Boehringer Mannheim Diagnostics, Indianapolis, IN, USA) on a Roche Cobas Fara analyzer (Roche Diagnostics, Indianapolis, IN, USA). HDL cholesterol was quantified with the above cholesterol method after precipitation of non-HDL cholesterol with magnesium/dextran. For samples with triglycerides Ͻ400 mg/dL, LDL cholesterol was estimated by Friedewald's formula. For samples with triglycerides Ͼ400 mg/dL, LDL cholesterol was determined after removal of very low density lipoprotein (VLDL) by ultracentrifugation.
NMR analysis of lipoproteins
Lipoprotein subclass levels and mean VLDL, LDL, and HDL particle diameters were measured on freshly thawed (0.25 mL) serum specimens using a 400 MHz proton NMR analyzer from LipoScience, Inc. (Raleigh, NC, USA), as previously described [18] . Spectra of each sample were acquired in duplicate at 47ЊC and the lipid methyl group signal envelope at 0.8 ppm deconvoluted to give lipoprotein subclass concentrations. Results included levels of 6 VLDL subclasses, IDL, 3 LDL subclasses, 5 HDL subclasses, mean diameter of VLDL, LDL, and HDL, and LDL particle concentration. NMR convention is that larger subclass descriptor numbers denote larger particles. Data for VLDL and HDL subclasses suggested that subclass regrouping was appropriate to simplify data analysis. For data analysis, VLDL subclasses were regrouped as large (V6, V5), medium (V4, V3), and small (V2, V1) subclasses, and HDL subclasses as large (cardioprotective H5, H4, H3) and small (non-cardioprotective H2, H1) subclasses. The subclass designations and their approximate diameter (nm) ranges, determined by calibration using purified subfractions analyzed by electron microscopy (VLDL and LDL), or polyacrylamide gradient gel electrophoresis (HDL), are as shown in Figure 1 . The IDL and LDL subclass diameters, which are uniformly ϳ5 nm smaller than those estimated by gradient gel electrophoresis, are consistent with both electron microscopy and lipid compositional data [18] .
Bulk lipid mass concentrations of chylomicrons and VLDL subclasses (V1 to V6) are reported in units of triglyceride (mg/dL) and those of IDL, LDL (L1 to L3), and HDL (H1 to H5) subclasses in units of cholesterol (mg/dL). Average VLDL, LDL, and HDL particle sizes (nm diameter) were determined by weighing the relative mass percentage of each subclass by its diameter. LDL particle concentrations (nmol/L) are the sums of the particle concentrations of the individual LDL subclasses.
Analysis of fresh and previously frozen serum from 379 subjects from the general population demonstrated lack of significant effect of a single freeze thaw cycle on the NMR spectra of serum. Acute glucose addition to nondiabetic sera and nonenzymatic glycation of lipoproteins isolated by sequential ultracentrifugation from nondiabetic subjects did not alter the NMR spectra 
Apolipoproteins and Lp(a) levels
Nephelometric assays (Beckman, Brea, CA, USA) were used according to the manufacturer's instructions to determine serum ApoA1, ApoB, and Lp(a).
LDL oxidizibility
LDL (d ϭ 1.019 to 1.063 g/mL) was isolated from plasma by sequential ultracentrifugation. Oxidizibility of the lipid component of LDL was determined by modification of the method of Esterbauer, as described [19] . Briefly, EDTA was removed from LDL by size exclusion chromatography on Sephadex G-25 columns, diluted to 100 g/mL cholesterol, and exposed to Cu ϩϩ ions (final concentration 5 mol/L) at 30ЊC. Results are expressed as the change in absorbance (⌬ absorbance) at 234 nm from baseline to peak absorbance (reflecting conjugated diene formation). Oxidizibility of the protein component was determined in the same sample from the development of fluorescence (Ex 360 nm/Em 430 nm) under the same conditions, expressed as the ratio of fluorescence at 24 hours' exposure to Cu ϩϩ to baseline fluorescence. 
Statistical analyses
Descriptive data in Tables 1 through 7 are mean [standard error of the mean (SE)]. For the analyses examining differences between treatment groups (Table 1) , we used a two-sample t test assuming equal variances or a chisquare test (1 d.f.). For the analyses examining differences between the 3 AER or creatinine clearance groups as a categorical variable (Table 2) , we used a multivariate analysis of variance (MANOVA) assuming equal variances or a chi-square test. To examine whether lipoprotein-related parameters predicted trends in AER, we treated log-transformed AER as a continuous dependent variable in 3 regressions. In the first, only the lipoproteinrelated parameter was included as an independent variable in the model. In the second, a standard set of covariates (obtained concurrently with sample collection) was added, including age, diabetes duration, HbA1c, hypertension, body mass index, waist-hip ratio, and DCCT randomization group. These analyses were done separately for women, men, and both genders combined. When the analysis was conducted for the total group, gender was included as an additional independent variable in the model. In the third regression, we tested for interactions between the specified lipoprotein parameter and gender using the same set of covariates (i.e., to assess whether the relationship between the lipoprotein-related parameter and renal status was the same for males and females). Similar analyses were performed with creatinine clearance replacing AER as the dependent variable. Table 1 presents clinical characteristics of the subjects in whom detailed lipoprotein profiles were obtained, according to gender and former DCCT randomization. Significant differences between the original DCCT intensive and conventional treatment groups are demonstrated for nephropathy and retinopathy status, as described recently for the entire cohort [15] . For AER, the difference was significant when AER was considered as a continuous variable or as a categorical variable (Ͻ40 or Ն40 mg/ 24 hr). There is also a persisting difference in current HbA1c between prior DCCT treatment groups for men, although this is small compared with the difference that was maintained (for both genders) during the DCCT [12] . Additionally, women in the former intensive management group were significantly heavier than women in the former conventional management group, and less likely to be taking angiotensin-converting enzyme (ACE) inhibitors; neither of these differences was significant for male participants. Plasma lipid profiles and serum NMR-LSP (not shown in Table 1 ) did not differ between subjects (of either gender) grouped according to prior DCCT [20] , and for this reason data for men and women were analyzed separately. Table 2 presents clinical characteristics of study subjects according to AER status. Compared with subjects with normal AER, those with increased AER were more likely to have been randomized to conventional treatment during the DCCT, to be male, and to smoke. Subjects with elevated AER had longer diabetes duration, higher blood pressure, more severe retinopathy, higher current HbA1c, and were more likely to be receiving anti-hypertensive or lipid-lowering drugs. Tables 3 through 6 Table 3 presents results for the conventional lipid profile. In the multivariate analysis, triglycerides, total and LDL cholesterol are significantly related to AER in women, men, and the total cohort. HDL cholesterol was not associated with AER. There were no significant gender interactions with these parameters. Tables 4 and 5 present NMR-LSP results. Table 4 summarizes data for the individual lipoprotein subclasses. Many of the NMR-determined parameters were associated with (log) AER (analyzed as a continuous variable) by univariate analysis, but we will emphasize results of the multivariate analysis in order to identify independent associations. In multivariate analysis, large VLDL was associated with AER in men and the total cohort, and medium and small VLDL were strongly associated with men and women. IDL was associated with AER in men only. None of the LDL subclasses was associated with AER. Nevertheless, as shown in Table 4 , in men, the LDL subclass peak shifts with increasing AER; in the presence of normal AER the major LDL peak is L3, in microalbuminuria it is L2, and in albuminuria it is the smallest, L1. For the 2 HDL subclasses, small HDL was positively associated with AER in men and the total cohort, while large HDL exhibited a borderline negative association in the total cohort. Table 5 presents data for the NMR-derived mean particle size (for VLDL, LDL, and HDL) and LDL particle concentration. In multivariate analysis in men, there was an inverse association between LDL diameter and AER, indicative of a shift from large to smaller LDL particles with increasing AER. In men and the total cohort there was also observed a significant positive association between LDL particle concentration and AER. Table 6 presents the results of the association between AER and apolipoprotein and Lp(a) levels and LDL oxidizibility. Among this set of determinations, only ApoB in men and in the whole cohort was significantly associated with AER by multivariate analysis. In men only, there was a borderline association of ApoA1 with AER. No associations were observed with levels of Lp(a) or log Lp(a) (data not shown), or with the oxidizibility of the protein or lipid components of isolated LDL in either gender or the combined groups.
RESULTS
We also analyzed our data to determine whether lipoprotein parameters were associated with creatinine clearance. For this analysis, subjects were categorized as having normal, elevated, or low creatinine clearance. Normal creatinine clearance was considered to be 97 to 137 mL/ min for men, and 88 to 128 mL/min for women [17] (total cohort data shown in Table 7 ). In regression analyses (as for AER), creatinine clearance was analyzed as a continuous variable. Associations were generally similar to that of AER. Using the same covariates as listed above, the following lipoprotein parameters were found to be significantly associated (P Ͻ 0.05) with worsening nephropathy as assessed by creatinine clearance: women, conventional profile, triglycerides; NMR-LSP: medium and small VLDL; ApoB, ApoA1; men, conventional profile, no associations; NMR-LSP: small VLDL, small LDL, LDL size (inverse), LDL particle concentration; ApoB (data not shown); total cohort, conventional profile, triglycerides; NMR-LSP: large VLDL, small VLDL, small LDL, LDL size (inverse), and LDL particle concentration; ApoB, ApoA1.
DISCUSSION
We conducted detailed lipoprotein analyses, including enzymatic lipid assays, NMR lipoprotein profiles, and apolipoprotein measures in serum and LDL oxidizibility, in a representative subset of the DCCT/EDIC cohort of subjects with type 1 diabetes. Nephropathy was independently associated with an adverse lipoprotein profile, which differed between men and women, and resembled that related to insulin resistance and cardiovascular disease. In general, renal dysfunction was associated with elevated triglyceride rich lipoprotein subclasses, a shift toward small LDL particles and small HDL subclasses. HDL-cholesterol, ApoA1 and Lp(a) levels, and the susceptibility of LDL to in vitro oxidation were not related to nephropathy.
Intensive diabetes management, as during the DCCT, is associated with better glycemic control, and also with significantly lower triglycerides, LDL cholesterol, and ApoB [21] . This observation, and data from cross-sectional and some prospective studies [5, 7, 22, 23] , is in keeping with dyslipidemia-promoting diabetic nephropathy. Mitigating this dyslipidemia may have conferred some of the still evident renal benefits of intensive diabetes management in the DCCT.
The DCCT/EDIC cohort is a large and well-characterized type 1 diabetes cohort, with an ongoing accumulation of clinical, biochemical, and genetic data. The cohort was studied at a time when the difference in HbA1c between former DCCT randomization groups that influenced the lipoprotein profile [20] had almost disappeared. By employing the novel NMR technique, which is highly efficient in terms of time, labor, sample volume, and cost, we have been able to define in great detail the associations between lipoproteins and nephropathy status, and to relate findings with this novel technique to other lipoprotein assessment techniques. Numerous potentially pro-atherogenic and insulin resistance-related associations between lipoprotein-related parameters and nephropathy were observed. These associations were generally strongest in univariate analyses, but as other parameters, such as glycemia and body habitus, may influence or be strongly associated with lipoproteins, we will emphasize results of the more rigorous multivariate analyses. In the conventional lipid profile, total triglyceride, total-and LDL cholesterol levels were associated with AER in both genders, in agreement with the earlier literature [6, 24] . In contrast, HDL cholesterol was not associated with AER. Regarding the relationship between total triglycerides and AER, NMR-LSP revealed that this is attributable to increases in all 3 VLDL subclasses in men, and medium and small VLDL in women. For women, no other lipoprotein parameters were independently associated with AER. Specifically, despite the association of conventional (calculated) LDL-cholesterol with AER, none of the individual LDL subclasses was related to nephropathy. In contrast, for men, multiple associations with lipoprotein subclasses were observed; IDL, LDL particle concentration, small (non-cardioprotective) HDL, and ApoB were all associated with AER, and LDL particle diameter exhibited a borderline inverse association. Also in men, but not in women, shifts in the Abbreviations are: ApoB, apolipoprotein B; ApoA1, apoprotein A1; LDL, low-density lipoprotein; HbA 1c , hemoglobin A 1c ; BMI, body mass index; WHR, waist to hip ratio. P 1 test for trend, dependent variable is log AER, independent variable is specified lipoprotein-related parameter. P 2 test for trend, dependent variable is log AER, independent parameter adjusted age, (gender for total cohort), duration of diabetes, hypertension, HbA 1c , BMI, WHR, and DCCT randomization group. P 3 test for interaction between specified lipid parameter and gender; covariates as for P proportion of large:small LDL (L3:L1) and large:small HDL were observed as AER increased. These shifts were toward a more atherogenic lipoprotein profile (i.e., a higher proportion of smaller LDL and smaller HDL particles). The greater association of lipid parameters and AER in men than in women may contribute to the higher susceptibility of men to nephropathy [25, 26] . The men in our cohort have significantly less favorable lipoprotein profiles than women, and had higher AER [20] (Table 1) . With respect to nephropathy, the NMR lipoprotein analysis provided additional information to that gained from the conventional lipid profile. While the findings from NMR-LSP in relation to VLDL subclasses essentially confirmed the association observed with total triglyceride in the conventional lipid profile, the findings relating to IDL levels, LDL particle concentration, shifts in LDL size, and small HDL in men could not be discerned from the conventional profile. IDL is not measured in the conventional analysis, and consistent with our findings, Sibley et al [6] , using density gradient ultracentrifugation in a cross-sectional analysis of the DCCT cohort at close-out, demonstrated increased IDL cholesterol in microalbuminuric and albuminuric subjects compared with normoalbuminuric subjects. Winocour et al [27] and Groop et al [28] also demonstrated increased IDL in cross-sectional studies of micro-versus normoalbuminuric subjects with type 1 diabetes. For LDL, our finding of a shift toward smaller particles with increasing AER supports the findings of Sibley et al [6] , but not those of Lahdenpera et al [5] , who found no association between LDL density distribution and AER in type 1 diabetes. Concerning HDL, a 10-year prospective study predominantly of subjects with type 1 diabetes identified low HDL cholesterol as a risk factor for renal disease [23] , but HDL subclasses were not assessed. The lack of a relationship between enzymatic HDL cholesterol levels and AER in the current study can be explained by the fact that large and small HDL subclasses had an opposite association with nephropathy.
ApoB, which is present on VLDL, LDL, IDL, and Lp(a), was associated with AER in men and in the entire cohort. In a cross-sectional study Attman et al [29] also demonstrated higher ApoB levels in subjects with type 1 diabetes with nephropathy relative to nephropathy-free type 1 diabetic subjects and healthy controls. Elevated ApoB confers an increased risk of coronary disease, and, consistent with our findings in the present study, has been associated with an accelerated decline in glomerular filtration rate in type 1 diabetic subjects with nephropathy [30] . Using immunoprecipitation techniques, Samuelsson et al [7] and Attman et al [8] revealed that the association of ApoB with the rate of progression of (nondiabetic) renal disease could be attributed to the triglyceride-rich apoB-containing lipoproteins, and that cholesterol-rich ApoB-containing lipoproteins, including LDL, were not implicated. These data are consistent with our finding that NMR-determined VLDL subclasses are more strongly associated with AER than LDL subclasses.
For ApoA1, we found borderline (P ϭ 0.06) positive associations with AER in men only, but other studies have demonstrated lower serum ApoA1 in nephropathic subjects [31, 32] and even more marked reductions in interstitial fluid ApoA1 levels in type 1 diabetic subjects with nephropathy [33] . No association of Lp(a) with nephropathy was found. Previous small cross-sectional studies in diabetic subjects have reported either increased or unchanged Lp(a) levels with increased AER [34] [35] [36] [37] . In a retrospective longitudinal study of subjects with diabetes, Lp(a) levels increased with rising AER [38] . In previous DCCT-based studies of Lp(a), lower Lp(a) levels were noted in the intensive versus conventional management groups, but no difference according to AER was found [6, 34] . Due to the wide range of serum Lp(a) and the major influence of Lp(a) genotype on serum Lp(a), cross-sectional studies require large numbers of subjects per group and also benefit from Lp(a) genotype or phenotype analysis [39] , which reflects particle size and perhaps function. Lp(a) particle size has been more strongly related to progression of carotid atherosclerosis [40] and to survival in end-stage renal disease [41] than Lp(a) level, but studies specifically in diabetes are lacking.
We were unable to find any association between LDL "oxidizibility" and nephropathy. We previously demonstrated that oxidizibility of LDL from 15 type 1 diabetic patients with normal AER (and similar glycemic control to the present study cohort) did not differ from oxidizibility in 15 matched nondiabetic controls [19] . Others have found decreased resistance to oxidation of LDL from subjects with end-stage renal disease compared with healthy controls [42, 43] , but this may be attributable to the renal failure itself. To our knowledge there are no published studies comparing LDL oxidizibility in subjects with type 1 diabetes according to AER.
We also tested whether lipoprotein parameters were associated with creatinine clearance, and obtained findings broadly in agreement with those for AER. The general agreement between the 2 measures of nephropathy strengthens our conclusions.
Our study was cross-sectional, and could not address the extent to which associated dyslipidemia is a cause or an effect (or both or neither) of diabetic nephropathy. However, our related study of retinopathy [abstract; Lyons TJ et al, Diabetes 49(Suppl 1):1118P, 2000], another microvascular complication, provides some corroborative evidence. While it is known that renal function affects plasma lipoprotein profiles, it is less likely that diabetic retinopathy does so as well. We found numerous associations of the same lipoprotein parameters with retinopathy status (controlling for nephropathy, glycemia, and other pertinent variables) than in the present study. This finding supports the possibility that dyslipidemia may contribute to, and not just result from, diabetic microvascular disease. A retrospective longitudinal analysis of DCCT/EDIC samples including the NMR profiles in stored pre-nephropathy samples is in progress, and will clarify this important issue.
Longitudinal studies using conventional lipid profiles also provide evidence in favor of a contributory role for dyslipidemia in diabetic nephropathy [30, 44] . Mulec et al [30] showed that total cholesterol, triglyceride, and apoB were significant predictors of subsequent nephropathy. Other evidence for a contributory role for lipoproteins in diabetic nephropathy is found in studies demonstrating amelioration of renal disease with intervention to improve lipid profiles. Ellis et al [45] noted that a decrease in LDL cholesterol is associated with regression of proteinuria in subjects with type 1 diabetes. Treatment of dyslipidemia by diet and/or drugs retards progression of renal disease in type 1 and type 2 diabetic and nondiabetic subjects [8, 44] . The Pittsburgh Epidemiology of Diabetes Complications Study identified LDL cholesterol and triglycerides as predictors of microalbuminuria, observing significant gender differences in these associations [20] . Gender differences in each of the major lipoprotein classes were also apparent in the current study. They may be attributable to gender differences in the "nephrotoxic" or "nephroprotective" effects of lipoproteins or lipoprotein-related factors. Lipoprotein subclass distribution and HDL antioxidant activity is influenced by several enzymes, including lipoprotein lipase, hepatic lipase, lysolecithin cholesterol acyltransferase, cholesterol ester transfer protein, and paraoxonase; activity of these enzymes may be affected by hormone status. Gender differences relating to insulin resistance may also contribute to the observed differences in the NMR profile between genders and subjects with and without nephropathy; insulin resistance is known to be associated with dyslipoproteinemia determined by NMR [46] . Other aspects of lipoproteins and interactions with non-lipid factors (such as C reactive protein), which we did not assess in this analysis, may also contribute to the observed gender differences in the lipoprotein-renal disease association.
Dyslipidemia may be both a cause and an effect of renal disease. As this was a cross-sectional study we could not separate the events, but the retrospective longitudinal study in progress will provide further insight. Potential contributors to dyslipidemia may be the triggering of a generalized hepatic production of VLDL by albuminuria and its threat to plasma oncotic pressure. Renal loss of apolipoproteins and other factors modulating lipoprotein metabolism and the effects of renal dysfunction on enzymes, which influence lipoprotein subclass distributions such as such as CETP and LCAT, may also be contributory.
CONCLUSION
Our data show that in both women and men, a lipid profile characterized by high triglycerides (predominantly in the smaller VLDL subclasses) is associated with diabetic nephropathy. Furthermore, in men, high IDL, high LDL particle concentration, and a shift from larger toward smaller LDL, ApoB, and small (non-cardioprotective) HDL levels are all associated with nephropathy. This overall pattern, particularly in men, conforms to the well-recognized atherogenic dyslipidemia characteristic of insulin resistance and type 2 diabetes [9, 46] . Insulin resistance, central adiposity, and a positive family history of type 2 diabetes may be associated with higher nephropathy risk in type 1 diabetes [47] ; in light of the current data, the associated dyslipidemia may contribute. Our findings are consistent with the existence of common lipid-related risk factors for nephropathy and accelerated atherosclerosis in diabetes. Since there may be differential effects of lipoprotein subclasses on nephropathy risk, NMR lipoprotein analysis may prove a valuable means to identify and monitor intervention in subjects at high risk for complications, and may ultimately contribute to reducing the morbidity and mortality associated with type 1 diabetes.
